Oncotelic Therapeutics's latest marketcap:
As of 06/04/2026, Oncotelic Therapeutics's market capitalization has reached $22.17 M. According to our data, Oncotelic Therapeutics is the 37293th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 22.17 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | 247.38 M |
| Shares Out | 443.48 M |
| EPS (ttm) | 0.58 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/13/2026 |
Oncotelic Therapeutics's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 06/04/2026 | $22.17 M | -29.05% | 37293 |
| 12/31/2025 | $37.13 M | 160.46% | 46652 |
| 12/31/2024 | $14.26 M | -6.64% | 46350 |
| 12/29/2023 | $15.27 M | -13.24% | 44694 |
| 12/30/2022 | $17.6 M | -71.94% | 43011 |
| 12/31/2021 | $62.72 M | 225.64% | 41076 |
| 12/31/2020 | $19.26 M | 34.48% | 37965 |
| 12/31/2019 | $14.32 M | 35386 |
Company Profile
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for orphan oncology indications. Headquartered in Agoura Hills, California, the company is dedicated to advancing novel therapies for challenging medical conditions.
Key Drug Development Programs
- OXi4503: A promising treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
- OT-101: An antisense therapy targeting TGF-β2, currently in Phase 3 clinical trials for pancreatic cancer, glioblastoma, and potential applications in treating viruses such as SARS and coronavirus.
- CA4P: Under development for advanced metastatic melanoma.
- Intranasal Drug Delivery System: Designed for intra-nasal Apomorphine to address Parkinson’s Disease, erectile dysfunction, and female sexual dysfunction.
- Artemisinin: A natural derivative from the Asian herb Artemisia Annua, explored for therapeutic applications.
- AI-Based Technologies: Leveraging artificial intelligence to enhance drug development and commercialization support technologies.
Oncotelic Therapeutics is committed to pioneering cutting-edge solutions to improve patient outcomes in oncology and beyond.
Frequently Asked Questions
-
What is Oncotelic Therapeutics's (OTC-OTLC) current market cap?As of 06/04/2026, Oncotelic Therapeutics (including the parent company, if applicable) has an estimated market capitalization of $22.17 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Oncotelic Therapeutics (OTC-OTLC) rank globally by market cap?Oncotelic Therapeutics global market capitalization ranking is approximately 37293 as of 06/04/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.